Follow us on Twitter
twitter icon@FreshPatents


Prophylactic patents

      

This page is updated frequently with new Prophylactic-related patent applications.




 Met e 1 tropomyosin variants for use in allergen-specific immunotherapy patent thumbnailMet e 1 tropomyosin variants for use in allergen-specific immunotherapy
The present invention provides isolated met e 1 polypeptides and nucleic acids encoding the isolated polypeptides that can prevent and/or alleviate an allergic response to shellfish tropomyosin. The polypeptides are based on the shrimp tropomyosin met e 1 protein and have been modified to act as hypoallergens.
The Regents Of The University Of California


 Neuroprotective composition and  use patent thumbnailNeuroprotective composition and use
A therapeutic composition for treating brain injury comprising a polyarginine peptide of from 5 to 9 arginines, and further comprising 1 or more terminal cysteines. The composition is administered in therapeutically effective dosages prophylactically or as soon as possible post-injury in treating neuronal injury..
Wayne State University


 Acth prophylactic treatment of renal disorders patent thumbnailActh prophylactic treatment of renal disorders
Provided herein are methods for prophylactic treatment of renal disorders comprising administration of adrenocorticotropic hormone (acth), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual suspected of having, predisposed to, or at risk of developing a renal disorder. .
Rhode Island Hospital


 Agent for inducing interferon production containing lactic acid bacteria patent thumbnailAgent for inducing interferon production containing lactic acid bacteria
This invention provides an ifn inducer comprising, as an active ingredient, lactic acid bacteria and capable of inducing ifn production, an immunopotentiating agent or prophylactic agent against virus infection comprising such inducer, and a food or drink product comprising such ifn inducer and having ifn-inducing activity, immunopotentiating activity, or prophylactic activity against virus infection. The agent for inducing ifn production comprises, as active ingredients, lactic acid bacteria that can activate plasmacytoid dendritic cells (pdcs) and promote ifn production, such as lactococcus garvieae nbrc100934, lactococcus lactis subsp.
Kirin Holdings Kabushiki Kaisha


 Compositions and methods relating to treatment of infection patent thumbnailCompositions and methods relating to treatment of infection
Microbial keratitis is a sight threatening disorder and infections result in ocular pain, stromal destruction, corneal thinning and/or perforation, leading to vision loss, if untreated and the need for transplantation. Methods of treating bacterial infection of the cornea prophylactically or therapeutically in a subject, are provided according to aspects of the present invention which include administering an effective dose of glycyrrhizin, or a pharmaceutically acceptable salt, hydrate, solvate, ester, amide, isomer or derivative thereof characterized by anti-bacterial activity, to the subject..
Wayne State University


 Oral prophylactic device patent thumbnailOral prophylactic device
A mask is provided to cover the face of a person. The mask can be attached to a person's face through an adhesive strip, which is connected along an interior surface of the mask.

 Amniotic fluid topical formulation patent thumbnailAmniotic fluid topical formulation
A human amniotic fluid formulation has been developed for topical application to the eye, which is useful for the treatment of ocular diseases and injuries including dry eyes, sjogren's syndrome, cataracts, burns and injuries to the eye tissues. The formulation is a sterile de-cellularized human amniotic fluid (d-haf), devoid of amniotic stem cells and elements of micronized membrane or chorion particles.
Mam Holdings Of West Florida, L.l.c.


 Therapeutic agent for ocular fundus disease patent thumbnailTherapeutic agent for ocular fundus disease
Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (s)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient..
Kowa Company, Ltd.


 Stabilized assembled nanostructures for delivery of encapsulated agents patent thumbnailStabilized assembled nanostructures for delivery of encapsulated agents
A non-covalently assembled hydrogel or organo-gel composition with serum stability is described. Low molecular weight (<2,500 da), generally regarded as safe (gras), materials assemble in the presence of a stabilizing agent at an appropriate molar percentage, forming hydrogel or organo-gel with nanostructures that resist disassembly or destabilization in serum for an extended period of time.
The Brigham And Women's Hospital, Inc.


 Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders patent thumbnailAmino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
The present invention relates to amino acid sequences that are directed against rank-l, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes..
Ablynx N.v.


Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof

The invention relates generally to variant activatable antibodies that include a masking moiety (mm), a cleavable moiety (cm), and an antibody (ab) that specifically binds to epidermal growth factor receptor (egfr), and to methods of making and using these variant anti-egfr activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.. .
Cytomx Therapeutics, Inc.

Cyaa-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses

The invention relates to a chimeric protein comprising or consisting of, from n-terminal to c-terminal, (a) a n-terminal part of a bordetella cyaa protein (b) a heterologous polypeptide, and (c) a c-terminal part of a bordetella cyaa protein. The invention also relates to a polynucleotide encoding a deleted version of a bordetella cyaa, as well as a polynucleotide encoding this chimeric protein.
Genticel

Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods

The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (vlps) which are useful in the treatment and prevention of human papillomavirus (hpv) infections and related disorders, including cervical cancer and persistent infections associated with hpv. Related compositions (e.g.
Stc.unm

Heterocyclic compound

Wherein each symbol is as described in the description, or a salt thereof has a superior pkc inhibitory action, and is useful as a prophylactic or therapeutic agent for immune diseases, inflammatory diseases and the like.. .

Targeted conjugates and particles and formulations thereof

Nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker have been designed. Such nanoparticles and microparticles can provide improved temporospatial delivery of the active agent and/or improved biodistribution.
Tarveda Therapeutics, Inc.

Replication-competent vsv-hiv env vaccines

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of aids. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention..
International Aids Vaccine Initiative

Immunogenic respiratory syncytial virus glycoprotein-containing vlps and related compositions, constructs, and therapeutic methods

The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (vlps) which are useful in the treatment and prevention of respiratory syncytial virus (rsv) infections and related disorders, including bronchiolitis and viral pneumonia. Related compositions (e.g.
Stc.unm

Nitroxides for use in treating or preventing diabetes and obesity

Pharmaceutical compositions are provided that are useful in treating diabetes. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of genes related to diabetes.
Mitos Pharmaceuticals, Inc.

Prophylaxis against cancer metastasis

This document provides prophylactic methods for reducing cancer metastasis by targeting lcn2, mmp9, and cx-cr4.. .
Board Of Regents, The University Of Texas System

Drug loaded microfiber sutures for ophthalmic application

Ophthalmic suture materials made from biocompatible and biodegradable polymers with high tensile strength for use in drug delivery, methods of making them, and method of using them for ocular surgery and repair have been developed. The suture materials are made from a combination of a biodegradable, biocompatible polymer and a hydrophilic biocompatible polymer.
The Johns Hopkins University

Anti-microbial immunomodulation

The invention provides methods of modulating an immune system in a vertebrate host for the therapeutic or prophylactic treatment of infection by a first microbial pathogen in a target tissue, comprising administration at an administration site of an effective amount of an antigenic formulation comprising antigenic determinants specific for a second heterologous microbial pathogen.. .
Qu Biologics Inc.

Allergen for prophylactic treatment of allergy

A composition comprising at least one first allergen, which is a respiratory allergen belonging to a first biological source material group, for use in prophylactic treatment of allergy to at least one second allergen, which is selected from the group consisting of a respiratory and a venomous allergen belonging to a second biological source material group and a food allergen of a food composition, in a subject, wherein the subject has not developed any clinical symptoms of allergy to the first allergen and to the second allergen, and wherein the first and second biological source material groups are not the same.. .
Alk-abellÓ A/s

Nucleic acid that inhibits expression of irf5

The present invention provides a nucleic acid having activity to suppress expression of irf5, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and the like.. .
Kyowa Hakko Kirin Co., Ltd.

Anti-inflammatory peptides and composition comprising the same

The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises at least one amino acid sequence among seq id no: 2 to seq id no: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides.
Gemvax & Kael Co., Ltd.

Fortifier

An agent enhances the therapeutic or prophylactic effect of a renin-angiotensin system inhibitor on renal diseases, including a specific prostaglandin i derivative such as beraprost sodium as an effective ingredient.. .
Toray Industries, Inc.

Insulin sensitisers and methods of treatment

The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome x, hyperglycaemia, vascular disease and kidney disease.
Naia Metabolic, Inc.

Melatonin and its use in preventing postoperative complications

The invention relates to the use of melatonin, either alone or in combination with at least one compound selected from the group consisting of l-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof, for the manufacture of a medicament for the therapeutic treatment, prophylactic treatment and/or prevention of postoperative infectious and/or non-infections complications induced by surgical interventions wherein the infectious complications may be pneumonia, wound infection (wound dehiscence), intra-abdominal abscess, and urinary tract infections (uti) or wherein the non-infectious complication may be anastomotic leak, a pharmaceutical formulation comprising melatonin and at least one compound selected from the group consisting of l-arginine, a physiologically acceptable salt thereof, one or more other physiologically acceptable compounds associated with the synthesis of nitric oxide and mixtures thereof and a method for the therapeutic and/or prophylactic treatment of postoperative infectious and/or non-infectious complications induced by surgical interventions.. .
Nutri-fit Gmbh & Co. Kg

Compositions and methods for modified dendrimer nanoparticle delivery

Compositions and methods for modified dendrimer nanoparticle (“mdnp”) delivery of therapeutic, prophylactic and/or diagnostic agent such as large reprna molecules to the cells of a subject have been developed. Mdnps efficiently drive proliferation of antigen-specific t cells against intracellular antigen, and potentiate antigen-specific antibody responses.
Whitehead Institute For Biomedical Research

Mesothelin vaccines and model systems

Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic t cell response.
The Johns Hopkins University

Attenuated viruses useful for vaccines

This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject.
The Research Foundation For The State University Of New York

Monoclonal antibodies against her2 epitope and methods of use thereof

This invention provides fully human monoclonal antibodies that recognize her2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications..
Mersana Therapeutics, Inc.

Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome

W is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring.. .

Vaccine delivery systems using yeast cell wall particles

The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making prophylactic and therapeutic vaccines..
Orbis Health Solutions, Llc

Prophylactic normalization of cutaneous wound repair

The present invention relates to methods of inhibiting scar formation in a skin wound as well as methods of promoting tissue regeneration in a skin wound in a subject in need thereof comprising administering in or near said wound an effective amount of one or more neurotoxins.. .

Method of dietary treatment for genetic and epigenetic diseases and disorders

Genetic and epigenetic diseases and disorders are treated with fda approved dietary compositions in the form of dietary supplements and nutraceuticals. The diseases and disorders to be treated include rett syndrome, trinucleotide repeat diseases such as fragile x syndrome, memory impairment, chronic inflammation, pre-cancerous conditions which involve cancer stem cells, and post-cancerous conditions which involve cancer stem cells which have survived in spite of cancer treatment.

Oxazolidine-based compound and selective androgen receptor agonist comprising same

Provided are novel selective androgen receptor agonists, a preparation method thereof, and a pharmaceutical composition including the same at a pharmaceutically effective amount. The selective androgen receptor agonists according to the present invention act on androgen receptors to increase androgen activity, thereby being usefully applied as a therapeutic and prophylactic agent for diseases or conditions, of which symptoms may be improved or may respond to treatment by increased activities of androgen receptors, namely, a variety of hormone-related diseases in male and female, muscle wasting disorders, osteoporosis, etc..
Dong-a St Co., Ltd.

Epitopes cross-reactive between hsv-1, hsv-2 and vzv and methods for using same

The invention provides epitopes of hsv and vzv that are cross-reactive and are useful for the prevention and treatment of alphaherpesvirus infection. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against whole virus.
University Of Washington

Norovirus deactivator and producing same, deactivating norovirus, producing lysozyme component for norovirus deactivation use, prophylactic or therapeutic agent for norovirus infection, and external preparation for skin for norovirus deactivation purposes

Provided is a norovirus deactivator, including a lysozyme component that includes at least one kind selected from lysozyme and/or a salt thereof, and a denatured product thereof.. .
Kewpie Corporation

Inhibitors for treating diseases characterized by atrial enlargement or remodeling

The present invention relates to the nep inhibitor pro-drug n-(3-carboxy-1-oxopropyl)-(4s)-p-phenylphenylmethyl)-4-amino-(2r)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof; or the nep inhibitor n-(3-carboxy-1-oxopropyl)-(4s)-p-phenylphenylmethyl)-4-amino-(2r)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling; a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the nep inhibitor or the nep inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. A human subject, in need of such treatment.
Novartis Ag

Method and system for network resource attack detection using a client identifier

Methods, systems, and techniques for network resource attack detection using a client identifier. A server receives from a device the client identifier and user credentials.
Wizard Tower Technoservices Ltd.

Nitrate- and nitrite-reducing probiotic feed additive

The present invention concerns novel probiotic compositions that increase nitrate- and nitrite-reduction in animals such as ruminants. The present invention thus provides compositions and methods for reducing nitrate/nitrite toxicity in such animals, or prophylactically protecting such animals from the effects of toxicity, such as methemoglobinemia.
The Texas A&m University System

Anti-pd1 antibodies, activatable anti-pd1 antibodies, and methods of use thereof

The invention relates generally to antibodies that specifically bind programmed cell death protein 1 (pd-1), activatable antibodies that specifically bind to pd-1 and methods of making and using these anti-pd-1 antibodies and anti-pd-1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.. .
Cytomx Therapeutics, Inc.

Prophylactic vaccine against egg drop syndrome (eds)

The present invention is intended to provide an egg drop syndrome (eds) vaccine that is capable of effectively preventing eds and can be stably supplied. The eds vaccine provided to this end contains as an active ingredient fused protein in which a polypeptide having a coiled-coil forming unit is bound to the knob region in the fiber protein of eds virus (edsv)..
Jectas Innovators Company Limited

Novel 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof

[wherein each symbol is as described in the description], which has a superior autotaxin inhibitory action and is useful as a prophylactic or therapeutic drug for diseases involving atx.. .

Antigens of pneumocystis murina and uses thereof

A surface protein of the murine fungal pathogen pneumocystis murina can be used to generate an immune response in a recipient animal or human that provides prophylactic protection and an anti-fungal activity in subjects already infected with a pneumocystis species. Further, the disclosure provides novel polypeptides or peptides derived from the p.
The University Of New Orleans

Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor

The present invention relates to dosing regimens with half-life extended factor viia (fviia) for prophylactic and “on-demand” treatment of bleeding, as well as for preventing a bleeding episode during or after surgery in patients with congenital or acquired bleeding disorders. The present invention further relates to the use of half-life extended fviia for treating or preventing blood loss in patients without bleeding disorders in situations of hemorrhage, i.e., due to trauma or surgery.
Csl Limited

Long-acting polymeric delivery systems

Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents.
Heron Therapeutics, Inc.

Influenza vaccine and therapy

The present invention is directed generally to m1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-m1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-m1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response..
Engen Bio, Llc

Immune response inducer

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the serex method using a cdna library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body.
Toray Industries, Inc.

Immune response inducer

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the serex method using a cdna library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body.
Toray Industries, Inc.

Immune response inducer

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the serex method using a cdna library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body.
Toray Industries, Inc.

Modulation of factor 11 expression

Disclosed herein are antisense compounds and methods for decreasing factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke.
Ionis Pharmaceuticals, Inc.

Long-acting polymeric delivery systems

Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents.
Heron Therapeutics, Inc.



Prophylactic topics:
  • Prophylactic
  • Antibodies
  • Nucleic Acids
  • Monoclonal
  • Nucleic Acid
  • Prophylactic Agent
  • Immunoglobulins
  • Immunoglobulin
  • Therapeutical
  • Bacillus Anthracis
  • Glutamic Acid
  • Liver Metastasis
  • Rectal Carcinoma
  • Membrane Protein
  • Colorectal Carcinoma


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Prophylactic for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Prophylactic with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.655

    file didn't exist2811

    479197 - 0 - 58